Physician profile
Kirsten Ann Hammersley
NPI 1861617920
$5,496.61
in general payments reported to CMS, 2019-2025
24 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $1,200 · 2024: $1,789 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,272 · Education: $14.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,271.97 |
| Education | $14.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.43 | 2022-2025 | |
| Axsome Therapeutics, INC. | $847.24 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $552.16 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $488.38 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $373.83 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $364.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $230.11 | 2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $172.37 | 2025 | |
| Supernus Pharmaceuticals, INC. | $169.30 | 2022-2024 | Qelbree, Qelbree |
| Corium, LLC | $165.71 | 2023-2025 | Azstarys |
| Avadel Cns Pharmaceuticals, LLC | $142.51 | 2023-2024 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $129.83 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $129.63 | 2023 | Spravato |
| Noven Therapeutics, LLC | $127.25 | 2023-2025 | Xelstrym, Secuado |
| Alkermes, INC. | $117.90 | 2024 | Lybalvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $84.15 | 2025 | |
| Bausch Health US, LLC | $50.74 | 2023-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $49.98 | 2024-2025 | Adzenys Xr-Odt |
| Biogen, INC. | $29.44 | 2025 | Zurzuvae |
| Tonix Medicines, INC. | $23.58 | 2025 | Tonmya |
| Collegium Pharmaceutical, INC. | $18.04 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $17.32 | 2025 | Relexxii |
| Harmony Biosciences LLC | $16.35 | 2025 | |
| Lundbeck LLC | $13.32 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsten Hammersley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.